Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-10-24

AUTHORS

Barnaby Hunt, Brian B. Hansen, Åsa Ericsson, Klaus Kallenbach, Sarah N. Ali, Tam Dang-Tan, Samuel J. P. Malkin, William J. Valentine

ABSTRACT

IntroductionOral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, encompassing glycemic control [defined in terms of glycated hemoglobin (HbA1c)], weight loss, and hypoglycemia. The present study assessed the cost of control with oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in the US.MethodsFour endpoints were evaluated: (1) HbA1c ≤ 6.5%; (2) HbA1c < 7.0%; (3) ≥ 1.0%-point HbA1c reduction and weight loss ≥ 3.0%; and (4) HbA1c < 7.0% without hypoglycemia and without weight gain. The proportions of patients achieving each endpoint were sourced from the PIONEER 2, 3 and 4 trials. Treatment costs were accounted over an annual time-period in 2019 US dollars (USD), based on wholesale acquisition cost. Cost of control was calculated by dividing treatment costs by the proportion of patients achieving each target.ResultsOral semaglutide was consistently associated with the lowest cost of control for all four endpoints. For the targets of HbA1c ≤ 6.5% and HbA1c < 7.0%, oral semaglutide 14 mg was associated with lower cost of control than empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg by USD 15,036, 14,697, and 6996, respectively, and USD 931, 346 and 4497, respectively. For the double composite endpoint, cost of control was lower with oral semaglutide 14 mg by USD 525, 32,277 and 13,011, respectively versus empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg. For the triple composite endpoint, cost of control was lower with oral semaglutide 14 mg by USD 1255, 7510 and 5774, respectively.ConclusionOral semaglutide was associated with lower cost of bringing patients with type 2 diabetes to four clinically-relevant treatment targets versus empagliflozin, sitagliptin, and liraglutide in the US.FundingNovo Nordisk A/S. More... »

PAGES

3483-3493

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-019-01125-y

DOI

http://dx.doi.org/10.1007/s12325-019-01125-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1122087621

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31650514


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon-Like Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liraglutide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sitagliptin Phosphate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Weight Loss", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hunt", 
        "givenName": "Barnaby", 
        "id": "sg:person.01346701147.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hansen", 
        "givenName": "Brian B.", 
        "id": "sg:person.01206630166.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206630166.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Scandinavia AB, Malm\u00f6, Sweden", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Novo Nordisk Scandinavia AB, Malm\u00f6, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ericsson", 
        "givenName": "\u00c5sa", 
        "id": "sg:person.0673311000.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673311000.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kallenbach", 
        "givenName": "Klaus", 
        "id": "sg:person.014143713363.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014143713363.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Inc, Plainsboro, USA", 
          "id": "http://www.grid.ac/institutes/grid.452762.0", 
          "name": [
            "Novo Nordisk Inc, Plainsboro, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ali", 
        "givenName": "Sarah N.", 
        "id": "sg:person.016334234763.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016334234763.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk Inc, Plainsboro, USA", 
          "id": "http://www.grid.ac/institutes/grid.452762.0", 
          "name": [
            "Novo Nordisk Inc, Plainsboro, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dang-Tan", 
        "givenName": "Tam", 
        "id": "sg:person.01074165727.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074165727.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malkin", 
        "givenName": "Samuel J. P.", 
        "id": "sg:person.012067446720.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valentine", 
        "givenName": "William J.", 
        "id": "sg:person.012655403464.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012655403464.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12325-019-00915-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112758608", 
          "https://doi.org/10.1007/s12325-019-00915-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0402-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101625666", 
          "https://doi.org/10.1007/s13300-018-0402-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-10-24", 
    "datePublishedReg": "2019-10-24", 
    "description": "IntroductionOral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, encompassing glycemic control [defined in terms of glycated hemoglobin (HbA1c)], weight loss, and hypoglycemia. The present study assessed the cost of control with oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in the US.MethodsFour endpoints were evaluated: (1) HbA1c \u2264\u20096.5%; (2) HbA1c <\u20097.0%; (3) \u2265\u20091.0%-point HbA1c reduction and weight loss \u2265\u20093.0%; and (4) HbA1c <\u20097.0% without hypoglycemia and without weight gain. The proportions of patients achieving each endpoint were sourced from the PIONEER 2, 3 and 4 trials. Treatment costs were accounted over an annual time-period in 2019 US dollars (USD), based on wholesale acquisition cost. Cost of control was calculated by dividing treatment costs by the proportion of patients achieving each target.ResultsOral semaglutide was consistently associated with the lowest cost of control for all four endpoints. For the targets of HbA1c \u2264\u20096.5% and HbA1c <\u20097.0%, oral semaglutide 14\u00a0mg was associated with lower cost of control than empagliflozin 25\u00a0mg, sitagliptin 100\u00a0mg and liraglutide 1.8\u00a0mg by USD\u00a015,036, 14,697, and 6996, respectively, and USD\u00a0931, 346 and 4497, respectively. For the double composite endpoint, cost of control was lower with oral semaglutide 14\u00a0mg by USD\u00a0525, 32,277 and 13,011, respectively versus empagliflozin 25\u00a0mg, sitagliptin 100\u00a0mg and liraglutide 1.8\u00a0mg. For the triple composite endpoint, cost of control was lower with oral semaglutide 14\u00a0mg by USD\u00a01255, 7510 and 5774, respectively.ConclusionOral semaglutide was associated with lower cost of bringing patients with type 2 diabetes to four clinically-relevant treatment targets versus empagliflozin, sitagliptin, and liraglutide in the US.FundingNovo Nordisk A/S.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-019-01125-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "oral semaglutide 14", 
      "proportion of patients", 
      "type 2 diabetes", 
      "composite endpoint", 
      "empagliflozin 25", 
      "sitagliptin 100", 
      "oral semaglutide", 
      "glucagon-like peptide-1 receptor agonists", 
      "short-term cost-effectiveness analysis", 
      "treatment targets", 
      "PIONEER clinical trial program", 
      "peptide-1 receptor agonists", 
      "weight loss", 
      "triple composite endpoint", 
      "clinical trial program", 
      "treatment costs", 
      "wholesale acquisition cost", 
      "cost-effectiveness analysis", 
      "HbA1c reduction", 
      "glycemic control", 
      "receptor agonist", 
      "semaglutide", 
      "trial program", 
      "patients", 
      "relevant treatment targets", 
      "weight gain", 
      "endpoint", 
      "HbA1c", 
      "hypoglycemia", 
      "empagliflozin", 
      "diabetes", 
      "sitagliptin", 
      "US dollars", 
      "trials", 
      "present study", 
      "acquisition costs", 
      "PIONEER 2", 
      "proportion", 
      "target", 
      "control", 
      "agonists", 
      "United States", 
      "treatment", 
      "loss", 
      "evaluation", 
      "study", 
      "reduction", 
      "program", 
      "uses", 
      "gain", 
      "s.", 
      "dollars", 
      "cost", 
      "analysis", 
      "low cost", 
      "cost of control", 
      "state"
    ], 
    "name": "Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States", 
    "pagination": "3483-3493", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1122087621"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-019-01125-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31650514"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-019-01125-y", 
      "https://app.dimensions.ai/details/publication/pub.1122087621"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_817.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-019-01125-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01125-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01125-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01125-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-019-01125-y'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      21 PREDICATES      99 URIs      89 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-019-01125-y schema:about N27753e79afb744d4bf977f56918f2a2b
2 N3709fa7a7dca4c2ab93d30bffea322d8
3 N39fc3637606a4ceca608b3ceab58221a
4 N43e70d93b24647f7849fbb83e41b50b4
5 N575f992425154a7ea4b1d42f8560ca69
6 N9cdeb41eb08744e7894c8c7a59e16ed8
7 N9eb623411b5c45f08b57a8d991fa0186
8 Na13b307d0533449bafc0fdbae151a54b
9 Nbebe9a071f5644deb09873943c640c0f
10 Nd73d95c1c569454d9ca289fcf2bf2d1d
11 Ndba06435cdb84892853cf3532e237c5d
12 Neb028dce5adf4535a09ec0d20dfe05a3
13 Nef601ab6f8e5480bbc87170ad58afc03
14 Nf6d3dd38c4d746cca5ea11d16b220563
15 Nfe397a5196ec41889d9b4e1f587009cb
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N3a8c5615fea842868f54f36d75320169
19 schema:citation sg:pub.10.1007/s12325-019-00915-8
20 sg:pub.10.1007/s13300-018-0402-8
21 schema:datePublished 2019-10-24
22 schema:datePublishedReg 2019-10-24
23 schema:description IntroductionOral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, encompassing glycemic control [defined in terms of glycated hemoglobin (HbA1c)], weight loss, and hypoglycemia. The present study assessed the cost of control with oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in the US.MethodsFour endpoints were evaluated: (1) HbA1c ≤ 6.5%; (2) HbA1c < 7.0%; (3) ≥ 1.0%-point HbA1c reduction and weight loss ≥ 3.0%; and (4) HbA1c < 7.0% without hypoglycemia and without weight gain. The proportions of patients achieving each endpoint were sourced from the PIONEER 2, 3 and 4 trials. Treatment costs were accounted over an annual time-period in 2019 US dollars (USD), based on wholesale acquisition cost. Cost of control was calculated by dividing treatment costs by the proportion of patients achieving each target.ResultsOral semaglutide was consistently associated with the lowest cost of control for all four endpoints. For the targets of HbA1c ≤ 6.5% and HbA1c < 7.0%, oral semaglutide 14 mg was associated with lower cost of control than empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg by USD 15,036, 14,697, and 6996, respectively, and USD 931, 346 and 4497, respectively. For the double composite endpoint, cost of control was lower with oral semaglutide 14 mg by USD 525, 32,277 and 13,011, respectively versus empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg. For the triple composite endpoint, cost of control was lower with oral semaglutide 14 mg by USD 1255, 7510 and 5774, respectively.ConclusionOral semaglutide was associated with lower cost of bringing patients with type 2 diabetes to four clinically-relevant treatment targets versus empagliflozin, sitagliptin, and liraglutide in the US.FundingNovo Nordisk A/S.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf Nceac37a51c77430ab90dcd1b24721223
27 Nd00f3089ea19480e8bec2aff694afd4a
28 sg:journal.1096634
29 schema:keywords HbA1c
30 HbA1c reduction
31 PIONEER 2
32 PIONEER clinical trial program
33 US dollars
34 United States
35 acquisition costs
36 agonists
37 analysis
38 clinical trial program
39 composite endpoint
40 control
41 cost
42 cost of control
43 cost-effectiveness analysis
44 diabetes
45 dollars
46 empagliflozin
47 empagliflozin 25
48 endpoint
49 evaluation
50 gain
51 glucagon-like peptide-1 receptor agonists
52 glycemic control
53 hypoglycemia
54 loss
55 low cost
56 oral semaglutide
57 oral semaglutide 14
58 patients
59 peptide-1 receptor agonists
60 present study
61 program
62 proportion
63 proportion of patients
64 receptor agonist
65 reduction
66 relevant treatment targets
67 s.
68 semaglutide
69 short-term cost-effectiveness analysis
70 sitagliptin
71 sitagliptin 100
72 state
73 study
74 target
75 treatment
76 treatment costs
77 treatment targets
78 trial program
79 trials
80 triple composite endpoint
81 type 2 diabetes
82 uses
83 weight gain
84 weight loss
85 wholesale acquisition cost
86 schema:name Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
87 schema:pagination 3483-3493
88 schema:productId N384859ffc4cf4a5fa3c34b80f419b6f7
89 N89ed94aef9c74395bac2394671a30753
90 Nb301e88772524c14a74f46f859f991f8
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122087621
92 https://doi.org/10.1007/s12325-019-01125-y
93 schema:sdDatePublished 2022-12-01T06:40
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher Na8564227704f4db9a41931952078a5a9
96 schema:url https://doi.org/10.1007/s12325-019-01125-y
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N07e4beebb75b4c4ba96289aee7b5ba73 rdf:first sg:person.012067446720.22
101 rdf:rest Nd37c997e25ad4fe48a488388f254260e
102 N27753e79afb744d4bf977f56918f2a2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Glucagon-Like Peptides
104 rdf:type schema:DefinedTerm
105 N281af3e9a8594193bd6413d4dc94ba98 rdf:first sg:person.01206630166.68
106 rdf:rest N88e2d58145724c26a1656a30d45bb3e2
107 N3709fa7a7dca4c2ab93d30bffea322d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Glycated Hemoglobin A
109 rdf:type schema:DefinedTerm
110 N384859ffc4cf4a5fa3c34b80f419b6f7 schema:name pubmed_id
111 schema:value 31650514
112 rdf:type schema:PropertyValue
113 N39fc3637606a4ceca608b3ceab58221a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Cost-Benefit Analysis
115 rdf:type schema:DefinedTerm
116 N3a8c5615fea842868f54f36d75320169 rdf:first sg:person.01346701147.33
117 rdf:rest N281af3e9a8594193bd6413d4dc94ba98
118 N43e70d93b24647f7849fbb83e41b50b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Diabetes Mellitus, Type 2
120 rdf:type schema:DefinedTerm
121 N575f992425154a7ea4b1d42f8560ca69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N88e2d58145724c26a1656a30d45bb3e2 rdf:first sg:person.0673311000.42
125 rdf:rest Nac946775a37c4287b2abf5dc22ec39ba
126 N89ed94aef9c74395bac2394671a30753 schema:name dimensions_id
127 schema:value pub.1122087621
128 rdf:type schema:PropertyValue
129 N9cdeb41eb08744e7894c8c7a59e16ed8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Middle Aged
131 rdf:type schema:DefinedTerm
132 N9eb623411b5c45f08b57a8d991fa0186 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Sitagliptin Phosphate
134 rdf:type schema:DefinedTerm
135 Na13b307d0533449bafc0fdbae151a54b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Liraglutide
137 rdf:type schema:DefinedTerm
138 Na8564227704f4db9a41931952078a5a9 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 Nac946775a37c4287b2abf5dc22ec39ba rdf:first sg:person.014143713363.96
141 rdf:rest Nf13d2eafea88419c8c40a5c003167aaa
142 Nb301e88772524c14a74f46f859f991f8 schema:name doi
143 schema:value 10.1007/s12325-019-01125-y
144 rdf:type schema:PropertyValue
145 Nbebe9a071f5644deb09873943c640c0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Benzhydryl Compounds
147 rdf:type schema:DefinedTerm
148 Nceac37a51c77430ab90dcd1b24721223 schema:issueNumber 12
149 rdf:type schema:PublicationIssue
150 Nd00f3089ea19480e8bec2aff694afd4a schema:volumeNumber 36
151 rdf:type schema:PublicationVolume
152 Nd37c997e25ad4fe48a488388f254260e rdf:first sg:person.012655403464.53
153 rdf:rest rdf:nil
154 Nd73d95c1c569454d9ca289fcf2bf2d1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name United States
156 rdf:type schema:DefinedTerm
157 Ndba06435cdb84892853cf3532e237c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Glucosides
159 rdf:type schema:DefinedTerm
160 Ndd4cd322076142cf8ee4274f229d921a rdf:first sg:person.01074165727.11
161 rdf:rest N07e4beebb75b4c4ba96289aee7b5ba73
162 Neb028dce5adf4535a09ec0d20dfe05a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Hypoglycemia
164 rdf:type schema:DefinedTerm
165 Nef601ab6f8e5480bbc87170ad58afc03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Hypoglycemic Agents
167 rdf:type schema:DefinedTerm
168 Nf13d2eafea88419c8c40a5c003167aaa rdf:first sg:person.016334234763.07
169 rdf:rest Ndd4cd322076142cf8ee4274f229d921a
170 Nf6d3dd38c4d746cca5ea11d16b220563 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Blood Glucose
172 rdf:type schema:DefinedTerm
173 Nfe397a5196ec41889d9b4e1f587009cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Weight Loss
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 sg:journal.1096634 schema:issn 0741-238X
183 1865-8652
184 schema:name Advances in Therapy
185 schema:publisher Springer Nature
186 rdf:type schema:Periodical
187 sg:person.01074165727.11 schema:affiliation grid-institutes:grid.452762.0
188 schema:familyName Dang-Tan
189 schema:givenName Tam
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074165727.11
191 rdf:type schema:Person
192 sg:person.01206630166.68 schema:affiliation grid-institutes:grid.425956.9
193 schema:familyName Hansen
194 schema:givenName Brian B.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206630166.68
196 rdf:type schema:Person
197 sg:person.012067446720.22 schema:affiliation grid-institutes:None
198 schema:familyName Malkin
199 schema:givenName Samuel J. P.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
201 rdf:type schema:Person
202 sg:person.012655403464.53 schema:affiliation grid-institutes:None
203 schema:familyName Valentine
204 schema:givenName William J.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012655403464.53
206 rdf:type schema:Person
207 sg:person.01346701147.33 schema:affiliation grid-institutes:None
208 schema:familyName Hunt
209 schema:givenName Barnaby
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
211 rdf:type schema:Person
212 sg:person.014143713363.96 schema:affiliation grid-institutes:grid.425956.9
213 schema:familyName Kallenbach
214 schema:givenName Klaus
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014143713363.96
216 rdf:type schema:Person
217 sg:person.016334234763.07 schema:affiliation grid-institutes:grid.452762.0
218 schema:familyName Ali
219 schema:givenName Sarah N.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016334234763.07
221 rdf:type schema:Person
222 sg:person.0673311000.42 schema:affiliation grid-institutes:None
223 schema:familyName Ericsson
224 schema:givenName Åsa
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673311000.42
226 rdf:type schema:Person
227 sg:pub.10.1007/s12325-019-00915-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112758608
228 https://doi.org/10.1007/s12325-019-00915-8
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s13300-018-0402-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101625666
231 https://doi.org/10.1007/s13300-018-0402-8
232 rdf:type schema:CreativeWork
233 grid-institutes:None schema:alternateName Novo Nordisk Scandinavia AB, Malmö, Sweden
234 Ossian Health Economics and Communications, Basel, Switzerland
235 schema:name Novo Nordisk Scandinavia AB, Malmö, Sweden
236 Ossian Health Economics and Communications, Basel, Switzerland
237 rdf:type schema:Organization
238 grid-institutes:grid.425956.9 schema:alternateName Novo Nordisk A/S, Søborg, Denmark
239 schema:name Novo Nordisk A/S, Søborg, Denmark
240 rdf:type schema:Organization
241 grid-institutes:grid.452762.0 schema:alternateName Novo Nordisk Inc, Plainsboro, USA
242 schema:name Novo Nordisk Inc, Plainsboro, USA
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...